News

The acquisition is Lilly’s latest push into genetic medicine, giving it a technology designed to overcome some of the field’s longstanding limitations.

The iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) is the rare fund that has spent the past year being publicly threatened by the President of the United States and quietly outperforming nearly every healthcare benchmark anyway. Trump signed his “most favored nation” drug pricing executive order last May, tying what Medicare pays to lower prices in other ... Ditch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?

Healthcare giants like Eli Lilly, Tandem Diabetes, Intuitive Surgical and ResMed are tapping aging-driven demand in obesity, surgery and sleep care.

Eli Lilly and Novo Nordisk are accelerating global obesity pill launches as rising GLP-1 demand puts weight-loss ETFs in focus.

Dell stock received two price-target hikes after the company detailed its strategy to capitalize on the AI megatrend.

The Fidelity MSCI Health Care Index ETF (NYSEARCA:FHLC) is down about 5% year to date while the S&P 500 is up 7%. Over five years, FHLC has returned 15% against about 80% for the S&P 500. If you bought FHLC for cheap sector diversification, fine. If you bought it expecting healthcare to keep pace with ... If You Hold This Healthcare ETF, You’re Losing Big

Emerging research shows there are ‘super-responders’ to GLP-1 drugs, and others who don’t respond at all.

This dark horse in the weight loss drug race is worth keeping on your watch list.

The company is riding an incredible tailwind.

Healthcare stocks rose late Monday afternoon, with the NYSE Healthcare Index and the State Street He

U.S. Supreme Court declined to hear Eli Lilly's appeal in a major whistleblower case tied to Medicaid rebates. The decision leaves in place a significant judgment related to allegations the company underpaid rebates to the government program. The ruling highlights legal and compliance risks around how pharmaceutical companies interact with U.S. government healthcare programs. Eli Lilly (NYSE:LLY) faces this legal setback with its stock at $1,004.92, after a gain of 3.9% over the past week...

Healthcare stocks rose Monday afternoon, with the NYSE Healthcare Index adding 0.4% and the State St

Eli Lilly (NYSE:LLY) is the stock everyone wants to talk about, and the reasons are obvious: Mounjaro revenue jumped 125% to $8.66 billion last quarter, the company raised full-year revenue guidance to $82 to $85 billion, and the market cap now sits at roughly $881.8 billion. But here’s what you should actually be watching. The ... Three Biotechs That Are Top Takeover Targets

Strong drug sales continue to drive growth, but expectations are climbing

Baxfendy gained FDA clearance for uncontrolled hypertension patients as AstraZeneca expands its cardiovascular and metabolic portfolio.

Drugmaker sees international markets as next test for obesity pill demand.

Novo Nordisk's (NYSE:NVO) oral version of its blockbuster weight-loss drug Wegovy continues to outpace its main competitor despite a slight weekly decline in prescriptions, according to Citi's latest tracking data. The bank's weekly prescription tracker, based on IQVIA data, showed Wegovy...

As next-generation GLP-1 contenders rise, key readouts are on the way from Pfizer, Viking Therapeutics and Eli Lilly.

Promising clinical trial data suggests big opportunity with Eli Lilly's retatrutide GLP-1 candidate.

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.

Eli Lilly recently reported detailed late-phase trial results showing that people with obesity were able to maintain long-term weight loss after switching to oral Foundayo or lower-dose Zepbound, while also committing an additional US$4.50 billion to expand its Indiana manufacturing network for obesity and genetic medicines. The combination of durable weight maintenance data for Foundayo and Zepbound and large-scale production expansion underscores how central obesity treatments have become...

Eli Lilly and Company (NYSE:LLY) is among the stocks with the best earnings growth for the next 10 years. On May 5, Emily Field from Barclays lifted the price target on Eli Lilly and Company (NYSE:LLY) to $1,400 from $1,350 and maintained an Overweight rating following the first-quarter results. In a research note, the analyst […]

There's a new challenger to the more established players in the weight-loss drug space.

Eli Lilly and Company (NYSE:LLY) is one of the Top 10 Stocks That Will Profit from AI. The company has recently introduced LillyPod, the pharmaceutical industry’s most powerful NVIDIA-powered supercomputer. Embedded with AI, Lillypod is part of a continuous learning system that accelerates drug discovery and development. On May 12, 2026, Eli Lilly and Company […]

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.4% in the afternoon session after the stock continued to rally as the company announced an additional $4.5 billion investment to expand its U.S. manufacturing capabilities as it prepares for surging demand for its weight-loss medications.

Picture a drug so popular that, even in markets where a cheaper generic competitor had just launched, it still grew by 10%. That's what happened to Eli Lilly's (LLY) Mounjaro in India recently. And it's the kind of detail that makes Morgan Stanley think Wall Street still isn't giving Lilly's ...

Eli Lilly (LLY) stock is back in focus after the company reported a very strong Q1, raised its full year revenue and earnings guidance, and released new obesity trial data on Foundayo and Zepbound. See our latest analysis for Eli Lilly. The recent obesity trial updates, expanded manufacturing plans and steady flow of product news have kept Eli Lilly in the spotlight. A 30 day share price return of 9.13% has helped the stock recover some ground after a year to date decline of 6.82%. The 1 year...

Biogen advances Alzheimer's drug diranersen to late-stage trials after a phase II study misses its main goal but shows cognitive and biomarker gains.

ABBV's Q1 beat is powered by Skyrizi and Rinvoq, whose strong sales growth offset Humira declines and boosts 2026 guidance.

Lance Roberts of RIA Advisors warned on the Thoughtful Money podcast that the S&P 500 has stretched so far above its key moving averages that a mean-reversion move could be a higher-probability scenario heading into the summer. “The big risk here is right now… we’ve got this massive deviation that’s going on kind of in ... Prediction. The S&P 500 Is So Far Above Its Moving Averages That a 10% Correction This Summer Is Not Out of the Question